A

Collaborate with us

At Adamed Discovery, we believe
collaboration is the most effective
way to turn scientific innovation
into real-world therapies.

Our partnering strategy is built on openness, scientific
rigour, and shared ambition, whether that means
bringing external innovations into our pipeline or joining
forces with global partners to advance our own assets
beyond proof of concept.

We welcome partnerships across discovery, development, and commercialization, working with biotech innovators, academic groups and pharmaceutical companies that share our vision of delivering meaningful advances in oncology, CNS disorders, and immunology.

Together, we can accelerate innovation and bring transformative treatments to patients worldwide.

Four individuals in lab coats examining a tablet together, engaged in a discussion or analysis.

Collaborate on
internal programs

Our goal is to bring differentiated,
science-driven assets to proof of concept,
then partner with leading biopharma companies
to take them through late-stage development
and commercialization.

We are seeking strategic partners with proven development and market access capabilities to help realize the full potential of our pipeline. Our partnership model is flexible and designed to create value through co-development, out-licensing, or joint ventures, depending on the stage and strategic fit of each program.

A woman in a lab coat holds a beaker containing a vibrant blue liquid, focused on her experiment.
A person in a lab coat examines an object with a focused expression in a laboratory setting.

What We Offer

  • Validated assets supported by strong preclinical
    and/or early clinical data packages
  • Integrated R&D and clinical operations through our in-house
    translational and phase I clinical expertise
  • Flexible partnership models tailored to each asset’s stage and strategic fit
  • Collaborative and transparent engagement with our scientific
    and business development teams

We welcome discussions with partners who share our ambition to turn promising science into global therapies that improve patients’ lives.

Contact our Business Development team to explore collaboration opportunities

Adamed Discovery’s
in-licensing strategy

A woman in a lab coat holds a beaker containing a vibrant blue liquid, focused on her experiment.
Partnering for First-in-Class Innovation
What We’re Looking For
At Adamed Discovery, we actively seek to in-license first-in-class therapeutics that
align with our expertise in oncology, CNS, and immunology. We are focused on advancing high-potential assets from preclinical proof-of-concept (PoC) to the clinic and beyond,
with the goal of delivering transformative treatments to patients faster. We welcome collaborations with academic institutions, biotech companies, and early-stage
ventures that share our commitment to rigorous science and translational impact.
01/04
What We Offer
  • Experienced scientific and clinical development team
  • End-to-end capabilities in protein engineering, bioprocessing,
    and translational pharmacology
  • Flexible deal structures tailored to each partner’s needs
  • Global perspective with operational reach across Europe and Asia
02/04
Let’s Advance Innovation Together
If you are developing a novel therapeutic with breakthrough potential
and are approaching IND readiness, we’d be excited to hear from you.
Contact our Business Development team to initiate a conversation
or submit a non-confidential package
03/04
Let’s Collaborate
We welcome strategic partnerships around our lead asset ONCO51
and our broader pipeline. Let’s shape the future of targeted
therapies — through in-licensing, co-development,
or joint exploration of emerging targets​.
04/04
Our Criteria

We are interested in biologics or small molecule assets that meet the following criteria:

STAGE

  • Animal PoC completed or robustly underway
  • At or near clinical candidate selection
  • Approximately 12–18 months from IND filing

INNOVATION

  • First-in-class mechanism of action
  • Strong scientific rationale and competitive differentiation